1. Home
  2. ZYME vs HELE Comparison

ZYME vs HELE Comparison

Compare ZYME & HELE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • HELE
  • Stock Information
  • Founded
  • ZYME 2003
  • HELE 1968
  • Country
  • ZYME United States
  • HELE United States
  • Employees
  • ZYME N/A
  • HELE N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • HELE Home Furnishings
  • Sector
  • ZYME Health Care
  • HELE Consumer Discretionary
  • Exchange
  • ZYME Nasdaq
  • HELE Nasdaq
  • Market Cap
  • ZYME 867.6M
  • HELE 713.2M
  • IPO Year
  • ZYME 2017
  • HELE N/A
  • Fundamental
  • Price
  • ZYME $13.30
  • HELE $21.75
  • Analyst Decision
  • ZYME Buy
  • HELE Hold
  • Analyst Count
  • ZYME 7
  • HELE 3
  • Target Price
  • ZYME $19.50
  • HELE $44.33
  • AVG Volume (30 Days)
  • ZYME 494.5K
  • HELE 981.2K
  • Earning Date
  • ZYME 07-31-2025
  • HELE 07-10-2025
  • Dividend Yield
  • ZYME N/A
  • HELE N/A
  • EPS Growth
  • ZYME N/A
  • HELE N/A
  • EPS
  • ZYME N/A
  • HELE N/A
  • Revenue
  • ZYME $93,384,000.00
  • HELE $1,862,473,000.00
  • Revenue This Year
  • ZYME $44.71
  • HELE $0.70
  • Revenue Next Year
  • ZYME $34.57
  • HELE $0.47
  • P/E Ratio
  • ZYME N/A
  • HELE N/A
  • Revenue Growth
  • ZYME 85.05
  • HELE N/A
  • 52 Week Low
  • ZYME $9.03
  • HELE $21.07
  • 52 Week High
  • ZYME $17.70
  • HELE $77.95
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 61.39
  • HELE 33.66
  • Support Level
  • ZYME $12.75
  • HELE $21.20
  • Resistance Level
  • ZYME $13.80
  • HELE $33.73
  • Average True Range (ATR)
  • ZYME 0.42
  • HELE 1.91
  • MACD
  • ZYME 0.07
  • HELE -0.48
  • Stochastic Oscillator
  • ZYME 79.88
  • HELE 9.18

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About HELE Helen of Troy Limited

Helen Of Troy Ltd is a consumer products company offering creative products and solutions for its customers through a diversified portfolio of brands. It has two operating segments: Home and Outdoor segment provides a broad range of consumer products for home activities such as food preparation, cooking, cleaning, and organization; as well as products for outdoor and on-the-go activities such as hydration, food storage, backpacks, and travel gear, and The Beauty and Wellness segment provides beauty and wellness products including mass and prestige market beauty appliances, prestige market liquid-based hair and personal care products, and wellness devices including thermometers, water and air filtration systems, humidifiers, and fans.

Share on Social Networks: